Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US

Dados Bibliográficos

ID4880169
AutoresSebastian Salas-Vega (0000-0003-3888-7113), Erin Shearer (0000-0002-5020-8016), Emily Shearer, Elias Mossialos (0000-0001-8664-9297)
Ano2020
Volume258
Páginas113042
Data de publicação2020-08-01
Peer ReviewedSim
Open AccessSim
TipoARTICLE
PeriódicoSocial Science & Medicine (JOURNAL)
Identificadores do periódicoISSN: 0277-9536 • E-ISSN: 1873-5347
EditoraElsevier BV (PUBLISHER)
DOI10.1016/j.socscimed.2020.113042
PMID32480184
OpenAlexW3024139281
IdiomaEN
Citações recebidas6
Referências citadas41

As cancer drug prices rise, it remains unclear whether the cost of new interventions is related to their beneficial impact for patients at a societal-level. Using data for 2003-2015 from the IQVIA MIDAS(R) dataset, the relationship between cancer drug costs and drug clinical benefits was studied in four countries with different approaches to drug pricing. Summary measures of drug clinical effects on overall survival, quality of life, and safety were obtained from a review of health technology assessments. Mean total drug costs for a full course of treatment were estimated using standard posology for each medicine and in each country. Regression analysis was used to test whether, at a societal-level, the cost of recently licensed drugs is related to their beneficial impact for patients. Across all eligible medicines, average treatment costs were lowest in France and Australia and highest in the UK and US. Compared with Australia, France, and the UK, cancer medicines were on average between 1.2 and 1.9 times more expensive in the US, where the average total per patient cost for treatment was $68,255.17. Costs for new cancer medicines are high and, at best, only weakly associated with drug clinical benefits. The strength of this relationship nevertheless varied across countries. Some new cancer drugs-particularly in the US-may be neither affordable nor clinically beneficial over existing treatments. While all countries can benefit from strategies that more robustly align price with therapeutic benefit in cancer drugs, the US stands out in its opportunity to improve both affordability and value in cancer drug treatment

Cancer · Cancer drugs · Drug · Environmental health · Health economics · Political science · Psychological intervention · Public health · Economic and Financial Impacts of Cancer · Health Systems, Economic Evaluations, Quality of Life · Medicine · Nursing · Pharmaceutical Economics and Policy · Internal Medicine · Pharmacology